for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

LivaNova PLC

LIVN.OQ

Latest Trade

71.18USD

Change

0.28(+0.39%)

Volume

60,002

Today's Range

70.70

 - 

71.57

52 Week Range

65.26

 - 

126.99

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
70.90
Open
71.14
Volume
60,002
3M AVG Volume
8.33
Today's High
71.57
Today's Low
70.70
52 Week High
126.99
52 Week Low
65.26
Shares Out (MIL)
48.39
Market Cap (MIL)
3,430.97
Forward P/E
23.17
Dividend (Yield %)
--

Next Event

Q3 2019 LivaNova PLC Earnings Release

Latest Developments

More

LivaNova Announces Q2 Worldwide Sales From Continuing Operations Of $277.2 Mln

Livanova Receives U.S. FDA 510(K) Clearance For Lifesparc Advanced Circulatory Support System

Livanova Comments On CMS Decision Regarding National Coverage Determination For VNS Therapy

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About LivaNova PLC

LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company's segments include Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products. Cardiac Surgery products include oxygenators, heart-lung machines, autotransfusion, mechanical heart valves and tissue heart valves. The Neuromodulation segment is engaged in the design, development and marketing of neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment resistant depression.

Industry

Medical Equipment & Supplies

Contact Info

20 Eastbourne Terrace

+44.20.33250662

http://www.livanova.com/home.action

Executive Leadership

Daniel Jeffrey Moore

Independent Chairman of the Board

Damien McDonald

Chief Executive Officer, Director

Thad Allen Huston

Chief Financial Officer

Trui Hebbelinck

Chief Human Resource Officer

Keyna Pidcock Skeffington

Senior Vice President, General Counsel

Key Stats

2.13 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

1.2K

2017

1.0K

2018

1.1K

2019(E)

1.1K
EPS (USD)

2016

3.050

2017

3.540

2018

3.550

2019(E)

3.060
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.13
Price To Book (MRQ)
2.31
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
14.30
LT Debt To Equity (MRQ)
11.76
Return on Investment (TTM)
-12.22
Return on Equity (TTM)
-9.97

Latest News

Latest News

BRIEF-LivaNova PLC Reports Qtrly Diluted Earnings Per Share From Continuing Operations $0.36

* LIVANOVA PLC - QTRLY WORLDWIDE SALES FROM CONTINUING OPERATIONS $250.4 MILLION, UP 5.3 PERCENT ON CONSTANT CURRENCY BASIS VERSUS Q1 2017

BRIEF-Livanova Bicarbon Aortic Valves Receive CE Mark

* LIVANOVA BICARBON AORTIC VALVES RECEIVE CE MARK FOR EXPANDED USE LABELING WITH LOWER-DOSE BLOOD THINNERS IN LOW-RISK PATIENTS Source text for Eikon: Further company coverage:

BRIEF-Livanova Plc To Evaluate Treatment Outcomes For Novel Microburst Vns Therapy System

* LIVANOVA COMMENCES CLINICAL STUDY TO EVALUATE TREATMENT OUTCOMES FOR NOVEL MICROBURST VNS THERAPY SYSTEM Source text for Eikon: Further company coverage:

BRIEF-Livanova Announces Enrollment For PERFECT Perceval Valve Clinical Trial In China

* LIVANOVA ANNOUNCES ENROLLMENT FOR PERFECT PERCEVAL VALVE CLINICAL TRIAL IN CHINA

BRIEF-Microport Scientific Updates On Acquisition Of Business From Livanova PLC

* SELLER HAS AGREED TO SELL, CRM BUSINESS FOR AN INITIAL CONSIDERATION OF US$190 MILLION Source text for Eikon: Further company coverage:

BRIEF-Livanova Enters Agreement To Divest Cardiac Rhythm Management Business To Microport Scientific Corp

* LIVANOVA ENTERS INTO DEFINITIVE AGREEMENT TO DIVEST ITS CARDIAC RHYTHM MANAGEMENT BUSINESS FRANCHISE TO MICROPORT SCIENTIFIC CORPORATION

BRIEF-Livanova To Acquire Tandemlife

* LIVANOVA PLC - LIVANOVA HAS AGREED TO PAY UP TO $250 MILLION FOR TANDEMLIFE

BRIEF-Livanova Initiates Believe Aortic Heart Valve Study In The U.S., Canada

* LIVANOVA INITIATES BELIEVE AORTIC HEART VALVE STUDY IN THE U.S. AND CANADA

BRIEF-LivaNova Commences Global Restore-Life Study For Treatment-Resistant Depression

* LIVANOVA COMMENCES GLOBAL RESTORE-LIFE STUDY FOR TREATMENT-RESISTANT DEPRESSION Source text for Eikon: Further company coverage:

BRIEF-Livanova To Acquire Imthera Medical

* LIVANOVA PLC SAYS ENTERED INTO AN AGREEMENT TO ACQUIRE REMAINING OUTSTANDING INTERESTS IN IMTHERA MEDICAL, INC.

BRIEF-Microport Scientific's unit buys CRM business from Livanova

* Unit buys CRM business for initial consideration of US$190 million from Livanova PLC Source text for Eikon: Further company coverage: (bangalore.newsroom@thomsonreuters.com)

BRIEF-LivaNova Plc reports ‍Q3 diluted earnings per share were $0.57​

* LivaNova Plc - Q3 2017 diluted earnings per share were $0.57

BRIEF-Livanova receives FDA approval for Vagus Nerve Stimulation Therapy system​

* Livanova receives FDA approvals for SenTiva device and next-generation VNS therapy programming system for treatment of epilepsy

BRIEF-Livanova and Microport announce approval of Rega pacemakers by China FDA

* Livanova and Microport announce the approval of Rega pacemakers by the China Food and Drug Administration

BRIEF-Livanova announces U.S. Launch of Optiflow Arterial Cannulae Family

* Says received FDA 510(k) clearance for U.S. Market launch of its Optiflow Arterial Cannulae Family Source text for Eikon: Further company coverage:

BRIEF-LivaNova ‍expects to achieve revenue growth in mid-single-digits in near term and high-single-digits in long term​

* LivaNova Plc - Expects to achieve revenue growth in mid-single-digits in near term and high-single-digits in long term

BRIEF-Livanova ‍Q2 adjusted EPS $1.01​

* Q2 earnings per share view $0.82, revenue view $315.6 million -- Thomson Reuters I/B/E/S

BRIEF-VNS Therapy receives FDA approval for expanded MRI Labeling

* VNS Therapy receives FDA approval for expanded mri labeling

BRIEF-Livanova announces Thad Huston as chief financial officer

* Livanova Plc - Thad Huston will join company as its new chief financial officer effective May 20, 2017

BRIEF-LivaNova acquires Caisson Interventional, LLC

* Says acquisition will be dilutive to earnings for several years

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up